ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.09M | 5.73M | 6.42M | 6.52M | 6.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.00M | 6.84M | 7.58M | 7.74M | 8.45M |
| Operating Income | -6.00M | -6.84M | -7.58M | -7.74M | -8.45M |
| Income Before Tax | -25.34M | -25.80M | -26.55M | -8.29M | -8.84M |
| Income Tax Expenses | -851.70K | -851.70K | -854.70K | -3.00K | 6.70K |
| Earnings from Continuing Operations | -24.49 | -24.95 | -25.70 | -8.29 | -8.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.49M | -24.95M | -25.70M | -8.29M | -8.84M |
| EBIT | -6.00M | -6.84M | -7.58M | -7.74M | -8.45M |
| EBITDA | -4.70M | -6.84M | -7.57M | -7.74M | -8.45M |
| EPS Basic | -3.32 | -3.83 | -4.46 | -4.33 | -7.18 |
| Normalized Basic EPS | -0.63 | -0.97 | -1.35 | -2.71 | -4.48 |
| EPS Diluted | -3.32 | -3.83 | -4.46 | -4.33 | -7.18 |
| Normalized Diluted EPS | -0.63 | -0.97 | -1.35 | -2.71 | -4.48 |
| Average Basic Shares Outstanding | 28.79M | 23.80M | 17.65M | 10.90M | 6.92M |
| Average Diluted Shares Outstanding | 28.79M | 23.80M | 17.65M | 10.90M | 6.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |